Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue

• Published in: Scientific Reports
• Main Authors: Dimitrios Salgkamis, Emmanouil G. Sifakis, Susanne Agartz, Valtteri Wirta, Johan Hartman, Jonas Bergh, Theodoros Foukakis, Alexios Matikas, Ioannis Zerdes
• Format: Article
• Language: English
• Published: Nature Portfolio 2024-08-01
• Subjects: Formalin-fixed Paraffin-embedded; Preanalytical factors; Next-generation sequencing; Gene expression; Breast cancer
• Online Access: https://doi.org/10.1038/s41598-024-69285-8

Abstract Formalin-fixed paraffin-embedded (FFPE) tissue represents a valuable source for translational cancer research. However, the widespread application of various downstream methods remains challenging. Here, we aimed to assess the feasibility of a genomic and gene expression analysis workflow using FFPE breast cancer (BC) tissue. We conducted a systematic literature review for the assessment of concordance between FFPE and fresh-frozen matched tissue samples derived from patients with BC for DNA and RNA downstream applications. The analytical performance of three different nucleic acid extraction kits on FFPE BC clinical samples was compared. We also applied a newly developed targeted DNA Next-Generation Sequencing (NGS) 370-gene panel and the nCounter BC360® platform on simultaneously extracted DNA and RNA, respectively, using FFPE tissue from a phase II clinical trial. Of the 3701 initial search results, 40 articles were included in the systematic review. High degree of concordance was observed in various downstream application platforms. Moreover, the performance of simultaneous DNA/RNA extraction kit was demonstrated with targeted DNA NGS and gene expression profiling. Exclusion of variants below 5% variant allele frequency was essential to overcome FFPE-induced artefacts. Targeted genomic analyses were feasible in simultaneously extracted DNA/RNA from FFPE material, providing insights for their implementation in clinical trials/cohorts.